Teva rivals urge US court to expedite Copaxone suit
Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) who are developing a More...
US Supreme Court upholds Copaxone patent
The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015. The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...
FDA again delays decision on Copaxone patent
– The decision gives Teva more time to transfer patients to its better patent protected double dosage Copaxone. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has filed a petition More...
European Patent Office upholds Copaxone patent
– The European Patent Office ruled in favor of Teva in a patent opposition proceeding filed by Synthon and Mylan. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced More...
Teva and Mylan Settle Copaxone Patent Litigation in France, the UK and the Netherlands
– The companies have agreed to settle pending patent litigation involving Copaxone in the UK, Netherlands and France. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) More...